Clinical trial · Interventional
Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma
Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE compound,120 patients will recrive Maitake mushroom extract compound,120 patients will recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ginseng compound | Drug | — | UNRESOLVED |
| GLSE compound | Drug | — | UNRESOLVED |
| Maitake mushroom extract compound | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- GLSE compound group
- description
- GLSE compound 2g each time by mouth,twice a day for 42 days.
- interventionNames
- Drug: GLSE compound
- type
- EXPERIMENTAL
- label
- Maitake mushroom extract compound group
- description
- Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
- interventionNames
- Drug: Maitake mushroom extract compound
- type
- EXPERIMENTAL
- label
- Ginseng compound group
- description
- Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * lung cancer and breast cancer patients confirmed by surgery pathology; * ECOG physical stamina score of 0\~3 points; * Expected lifetime \> 3 months; * Need to receive radiation and chemotherapy; * Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L; * To follow-up, good adherence Exclusion Criteria: * Allergic to text drug; * Pregnancy or lactation women; * Suffering from mental illness of not easy to control, * Have serious mental or cognitive dysfunction; * Can not comply with the experimental scheme or can't cooperate with the follow-up; * The patients who are unfavorable to the subject.
References
Publications (0)
Data not yet available